title: Multihospital outbreak of Clostridium difficile infection, Cleveland, Ohio, USA.
abstract: To determine whether a multihospital Clostridium difficile outbreak was associated with epidemic strains and whether use of particular fluoroquinolones was associated with increased infection rates, we cultured feces from C. difficile-infected patients. Use of fluoroquionolones with enhanced antianaerobic activity was not associated with increased infection rates.
authors.affiliation: University Hospitals of Cleveland, Cleveland, Ohio, USA.
authors.forename: Robin L P
authors.initials: RL
authors.lastname: Jump
authors.forename: Michelle M
authors.initials: MM
authors.lastname: Riggs
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Sethi
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Pultz
authors.forename: Tracie
authors.initials: T
authors.lastname: Ellis-Reid
authors.forename: William
authors.initials: W
authors.lastname: Riebel
authors.forename: Dale N
authors.initials: DN
authors.lastname: Gerding
authors.forename: Robert A
authors.initials: RA
authors.lastname: Salata
authors.forename: Curtis J
authors.initials: CJ
authors.lastname: Donskey
mesh_terms: D000890:Anti-Infective Agents / Q000627:therapeutic use; D001372:Aza Compounds / Q000627:therapeutic use; D016360:Clostridioides difficile / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D003015:Clostridium Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D004196:Disease Outbreaks; D024881:Drug Resistance, Bacterial; D005243:Feces / Q000382:microbiology; D024841:Fluoroquinolones / Q000627:therapeutic use; D000077734:Gatifloxacin; D005798:Genes, Bacterial; D006761:Hospitals; D006801:Humans; D000077266:Moxifloxacin; D009820:Ohio / Q000453:epidemiology; D011804:Quinolines / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077734:Gatifloxacin; D000077266:Moxifloxacin
references.citation: Infect Control Hosp Epidemiol. 2007 Feb;28(2):198-201
references.pmid: 17265402
references.citation: Clin Infect Dis. 2008 Jul 1;47(1):56-62
references.pmid: 18491964
references.citation: J Clin Microbiol. 2002 Sep;40(9):3470-5
references.pmid: 12202595
references.citation: J Clin Microbiol. 2004 Sep;42(9):4316-8
references.pmid: 15365032
references.citation: Infect Control Hosp Epidemiol. 2001 Sep;22(9):572-5
references.pmid: 11732787
references.citation: Infect Control Hosp Epidemiol. 2005 Mar;26(3):273-80
references.pmid: 15796280
references.citation: Clin Infect Dis. 2005 Nov 1;41(9):1254-60
references.pmid: 16206099
references.citation: Clin Infect Dis. 2004 Mar 1;38(5):640-5
references.pmid: 14986246
references.citation: N Engl J Med. 2005 Dec 8;353(23):2433-41
references.pmid: 16322603
references.citation: J Antimicrob Chemother. 2006 Oct;58(4):891-4
references.pmid: 16880172
references.citation: Emerg Infect Dis. 2003 Jun;9(6):730-3
references.pmid: 12781017
references.citation: Antimicrob Agents Chemother. 2007 Aug;51(8):2674-8
references.pmid: 17562807
references.citation: N Engl J Med. 2005 Dec 8;353(23):2442-9
references.pmid: 16322602